Literature DB >> 18781859

Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.

Hedi Schelleman1, Nita A Limdi, Stephen E Kimmel.   

Abstract

Warfarin is a highly efficacious drug, but management of warfarin is difficult, in part because of the large interindividual maintenance dose differences. Warfarin dose requirements differ by race and it has been suggested that some of these differences are owing to genetic diversity. For example, persons of African descent have lower allele frequencies of the CYP2C9*2 and *3 and VKORC1 1173T allele, which have been associated with lower warfarin dose requirements in Caucasians. Since there is currently debate whether genetic information should be used in clinical practice to determine the starting dose for a warfarin initiator, it is of great importance to determine whether everyone will benefit from this knowledge.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781859     DOI: 10.2217/14622416.9.9.1331

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  24 in total

1.  Genetic warfarin dosing: tables versus algorithms.

Authors:  Brian S Finkelman; Brian F Gage; Julie A Johnson; Colleen M Brensinger; Stephen E Kimmel
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

2.  New genetic variant that might improve warfarin dose prediction in African Americans.

Authors:  Hedi Schelleman; Colleen M Brensinger; Jinbo Chen; Brian S Finkelman; Mark J Rieder; Stephen E Kimmel
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

3.  Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Authors:  Stuart A Scott; Rame Khasawneh; Inga Peter; Ruth Kornreich; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

4.  High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans.

Authors:  Erdal Cosgun; Nita A Limdi; Christine W Duarte
Journal:  Bioinformatics       Date:  2011-03-30       Impact factor: 6.937

Review 5.  Pharmacogenetics of warfarin dosing in patients of African and European ancestry.

Authors:  Aditi Shendre; Chrisly Dillon; Nita A Limdi
Journal:  Pharmacogenomics       Date:  2018-10-22       Impact factor: 2.533

6.  Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.

Authors:  Xiuling Zhang; Lei Li; Xinxin Ding; Laurence S Kaminsky
Journal:  Drug Metab Dispos       Date:  2011-05-11       Impact factor: 3.922

7.  Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.

Authors:  Stuart A Scott; Manishkumar Patel; Suparna Martis; Steven A Lubitz; Sarina van der Zee; Chang Yoo; Lisa Edelmann; Jonathan L Halperin; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2011-12-21       Impact factor: 2.533

8.  Inferring ethnicity from mitochondrial DNA sequence.

Authors:  Chih Lee; Ion I Măndoiu; Craig E Nelson
Journal:  BMC Proc       Date:  2011-05-28

Review 9.  Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Authors:  Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore
Journal:  Semin Thromb Hemost       Date:  2012-10-06       Impact factor: 4.180

10.  Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients.

Authors:  Alga S Ramos; Richard L Seip; Giselle Rivera-Miranda; Marcos E Felici-Giovanini; Rafael Garcia-Berdecia; Yirelia Alejandro-Cowan; Mohan Kocherla; Iadelisse Cruz; Juan F Feliu; Carmen L Cadilla; Jessica Y Renta; Krystyna Gorowski; Cunegundo Vergara; Gualberto Ruaño; Jorge Duconge
Journal:  Pharmacogenomics       Date:  2012-12       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.